Heron Therapeutics, Inc. (NASDAQ:HRTX) has a beta value of 1.71 and has seen 8,552,550 shares traded in the recent trading session. The company, currently valued at $1.28 Billion, closed the recent trade at $14.14 per share which meant it lost -$5.71 on the day or -28.81% during that session. The HRTX stock price is -89.6% off its 52-week high price of $26.81 and 32.11% above the 52-week low of $9.6. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.15 Million shares traded. The 3-month trading volume is 1.08 Million shares.

The consensus among analysts is that Heron Therapeutics, Inc. (HRTX) is a Buy stock at the moment, with a recommendation rating of 1.6. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 10 have rated it as a Hold, with 10 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.65.

Heron Therapeutics, Inc. (NASDAQ:HRTX) trade information

Despite being -29.26% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Jun 23 when the HRTX stock price touched $22.08- or saw a rise of 34.1%. Year-to-date, Heron Therapeutics, Inc. shares have moved -38.09%, while the 5-day performance has seen it change -32.23%. Over the past 30 days, the shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) have changed -20.14%. Short interest in the company has seen 17.05 Million shares shorted with days to cover at 15.79.

Heron Therapeutics, Inc. (HRTX) estimates and forecasts

Figures show that Heron Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -19.95% over the past 6 months, with this year growth rate of -6.8%, compared to 12.4% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -3.2% and -64.3% for the next quarter. Revenue growth from the last financial year stood is estimated to be -43.4%.

9 analysts offering their estimates for the company have set an average revenue estimate of $17.29 Million for the current quarter. 9 have an estimated revenue figure of $17.84 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $31.7 Million and $42.62 Million respectively for this quarter and the next, and analysts expect sales will grow by -45.5% for the current quarter and -58.1% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +2.7% over the past 5 years. Earnings growth for 2020 is a modest -2.5% while over the next 5 years, the company’s earnings are expected to increase by 47.5%.